Talon Private Wealth LLC Grows Position in United Therapeutics Corporation $UTHR

Key Points

• Talon Private Wealth LLC significantly increased its holdings in United Therapeutics Corporation by 5,823.7%, totaling approximately $1.79 million worth of shares in the first quarter.
• Wall Street analysts have shown optimism for United Therapeutics, with nine analysts rating the stock as a Buy and raising price targets, including Bank of America and Jefferies Financial Group.
• United Therapeutics reported a quarterly EPS of $6.41, missing estimates, while its revenue for the quarter was $798.6 million, also slightly below consensus expectations.

Talon Private Wealth LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 5,823.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,746 shares of the biotechnology company's stock after acquiring an additional 5,649 shares during the quarter. Talon Private Wealth LLC's holdings in United Therapeutics were worth $1,785,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. XTX Topco Ltd bought a new position in shares of United Therapeutics during the first quarter valued at approximately $313,000. Allianz Asset Management GmbH raised its holdings in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after acquiring an additional 33,254 shares in the last quarter. LPL Financial LLC raised its holdings in shares of United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after acquiring an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in shares of United Therapeutics during the first quarter valued at approximately $227,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Up 2.3%

Shares of NASDAQ UTHR traded up $9.18 during trading on Tuesday, reaching $403.80. The company had a trading volume of 644,818 shares, compared to its average volume of 885,064. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $436.95. The stock has a market cap of $18.22 billion, a PE ratio of 15.76, a P/E/G ratio of 6.02 and a beta of 0.62. The business's 50-day moving average is $312.09 and its 200 day moving average is $306.29.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same period in the prior year, the company posted $5.85 earnings per share. The company's revenue was up 11.7% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $385.21, for a total value of $4,237,310.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $14,168,409.01. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard Giltner sold 3,036 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 106,181 shares of company stock valued at $35,537,239. 10.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Jefferies Financial Group upped their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a research report on Thursday, September 4th. Oppenheimer upped their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $429.62.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.